S3 show the results for the outcome MACE: both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for MACE (13% and 11%, respectively) as compared with placebo, and a lower risk for MACE as compared with DPP-4 inhibitors (12% and 11%, respectively)
That said, some patients do report anecdotal flare-ups with acidic foods possibly related to individual gut sensitivity or specific microbiome composition
We have delivered medicines to more than 88 countries
The FDA has placed BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Melanotan II, Selank, Semax, and several others on lists of substances not approved for compounding, on grounds of immunogenicity risks, peptide-related impurities, and insufficient human safety data
The survey found 332 said they were taking a GLP-1 medication, but 151 said they no longer were on the medication